bovine rotavirus pentavalent vaccine

**Bovine rotavirus pentavalent vaccine** is a live, oral, pentavalent vaccine composed of five human-bovine reassortant rotaviruses targeting the common circulating G serotypes (G1, G2, G3, G4, and G9), indicated for the prevention of rotavirus gastroenteritis in infants and young children[1][3][5][4][7]. The vaccine mechanism involves inducing immunity against rotavirus through mucosal and systemic immune responses generated after administration. Its primary action is prevention, not therapy, of rotavirus infection. It has been shown to significantly reduce the incidence, severity, and hospitalizations related to rotavirus gastroenteritis, with efficacy rates typically between 66–74% for any severity and higher (~98–100%) for severe disease[3][7][9]. Developers and key manufacturers include Serum Institute of India (BRV-PV), Merck (RotaTeq), and Bharat Biotech (Rotasiil).

Brand names

RotasiilRotaTeq

Other names

bovine rotavirus pentavalent vaccinepentavalent rotavirus vaccinelive human-bovine reassortant rotavirus vaccineRV5RV-5RV 5